"Tumor Lysis Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
| Descriptor ID |
D015275
|
| MeSH Number(s) |
C15.604.515.880 C20.683.515.950
|
| Concept/Terms |
Tumor Lysis Syndrome- Tumor Lysis Syndrome
- Syndrome, Tumor Lysis
- Syndromes, Tumor Lysis
- Tumor Lysis Syndromes
- Tumour Lysis Syndrome
- Syndrome, Tumour Lysis
- Syndromes, Tumour Lysis
- Tumour Lysis Syndromes
|
Below are MeSH descriptors whose meaning is more general than "Tumor Lysis Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Tumor Lysis Syndrome".
This graph shows the total number of publications written about "Tumor Lysis Syndrome" by people in this website by year, and whether "Tumor Lysis Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 3 | 5 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Lysis Syndrome" by people in Profiles.
-
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. Clin Cancer Res. 2022 10 14; 28(20):4385-4391.
-
Oncologic Emergencies. AACN Adv Crit Care. 2021 Sep 15; 32(3):306-314.
-
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. Am J Hematol. 2021 03 01; 96(3):E65-E68.
-
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020 10 15; 13(1):137.
-
Oncologic emergencies in the emergency medicine residency curriculum: A national survey. Am J Emerg Med. 2020 11; 38(11):2477-2481.
-
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020 Feb; 7(2):e168-e176.
-
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.
-
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
-
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188.